#HFrEF

[moderntechbiz]

Understanding “HFREF” ICD-10 Classification

The ICD-10 code for HFREF is I50.2 - Systolic (congestive) heart failure. 🔹 I50.20: Unspecified 🔹 I50.21: Acute 🔹 I50.22: Chronic 🔹 I50.23: Acute on chronic

Always code accurately based on the patient's condition! 🩺

[yashmedica]

UK Heart Failure Drugs Market 2024: Segmentation, Leaders, and Future Trends

UK heart failure drugs market through the lens of segmentation (drug class, application, etc.) | Leading companies, latest advancements (gene therapy, combination therapies)

UK Heart Failure Drugs Market: A Segmented View for Healthcare Professionals (2024) The UK heart failure drugs market presents a dynamic landscape for healthcare professionals. With an aging population and rising heart disease prevalence, the demand for effective heart failure medications is expected to soar. This report delves into the market segmentation, highlighting key players, recent…

[hardoctornews]

Finerenone efficace nello scompenso cardiaco lieve o preservato anche con fibrillazione atriale

Nel contesto dello scompenso cardiaco con frazione di eiezione lievemente ridotta o preservata (HFmrEF/HFpEF), la fibrillazione atriale (AF) rappresenta una comorbidità frequente e rilevante. Un’analisi predefinita del trial randomizzato FINEARTS-HF, recentemente pubblicata su JAMA Cardiology, ha valutato l’efficacia e la sicurezza di finerenone, un antagonista non steroideo del recettore dei…

[appalachiananarchist]

Work-related rant here…

I have noticed that a lot of the colleagues in my area let so many "minor" abnormalities slide despite being signals of a larger problem. I have had patients walk in with really obvious abnormalities ongoing for years without any further investigation done. Example: I had a guy come in with a complaint of weight loss and joint pain. His skin looked weird. Did some basic labs - AST was 40, platelets were ~130. Obviously alarm bells started going off, so I checked his ferritin. It was 3500. Did genetic testing to confirm- hereditary hemochromatosis. It took me quite literally one visit to diagnose this man. Here's the annoying part: afterwards, he got me copies of labs from his previous providers. He had mild LFT elevations and mildly low platelets for years. He has been dealing with this, having damage done to his liver, for years because no one thought an AST 40 + PLT 130 was a combination worth investigating, despite his "unexplained" family history of death by liver cancer.

I would love for this to be a one-off event, but it isn't. I inherit "diet controlled" diabetics with double-digit A1Cs, patients with positive HCV ab testing and no follow up, people with a GFR <60 and no mention of kidney disease in their chart or renal dosing performed, HFrEF patients with no ACE-I/SGLT-2/BB etc, and just… ugh! I am so upset about this HH patient that now I all of my frustrations about shoddy local care are coming out. I just want people to pay attention. I feel like I am always cleaning up messes and I am tired of it.

[wintermelonmilktea]

Such a solid 3 days of work. Highlights include:

Caring for a pt w/ a new cancer dx. First day I worked w/ this pt, they were mean, untrusting, snappy - had a very flat affect. I was stern w/ them this time. Laid down the LAW! Told them we won’t be using a primafit & highly encouraging them to get up to use the BSC to build strength. Guess what happened that whole shift? Pt would call to get up to use BSC, even if it took 10 mins to get them up! I got them to ambulate 2x in the halls. The second day w/ this pt, they lit up when they saw me! Held my hand, I held theirs. Although, they seemed more exhausted & angry. Still encouraged them to take their meds, work w/ PT, ambulate, use the BSC… and convinced them to get a midline! Which they said was painless. Best decision ever! We started to build trust. Day 3, I worked w/ this pt again and encouraged the same things. Pt seemed to be in good spirits, and so much stronger today. They scared PT away, but I managed to convince the pt to work w/ them, then they ambulated the halls. 2x! Before I left, pt told NOC nurse I’m the sweetest, held my hand, and I gave them the biggest hug. They were my least fave on day 1, and one of my faves by day 3. I will miss them.

Getting in a successful IV insertion, w/ great blood return… I don’t know how I did it. But I was quick. It’s always a nice feeling. Like the IV hashira in me took over 😌

Taking care of my pt in sunglasses. We were together 3 days as well. They were the sweetest, and it was nice seeing them get to RA.

It’s interesting too. How your interactions w/ pts build trust, and allow them to be more comfortable/ trusting with you. Then how your assessments can rly make a difference in someone’s life or plan of care.

For ex:

Yday my pt was adm for a fall/ RLE wound. We put them on tele, for their HFrEF 48%, then throughout the night, they had 2-2.4 sec pauses, dipping to HR 30s. Endorsed N/V/SOB, dizziness. In the AM, I let the MD know. Plan of care totally changed. Did an ECHO on them and saw how the heart was poorly fxning. Now the new plan is for pt to get a pacemaker the following day. Imagine if that wasn’t noticed or passed on?! Wow

Anyways, lately I’ve been loving my job. Maybe it’s because I’m on days - but I’m really making a difference in peoples lives. I’m enjoying it so much! ♡

[drjerr]

CASO CLÍNICO COMENTADO: MANEJO DE IC-FEr CON HIPOTENSIÓN

Lectura previa: Manejo Clínico de la Hipotensión en Pacientes con Insuficiencia Cardíaca con Fracción de Eyección Reducida (HFrEF) 2025 PRESENTACIÓN DEL CASO Historia Clínica Paciente: Mujer de 72 años, María G. Antecedentes: IC-FEr diagnosticada hace 18 meses (FEVI 32%) Hipertensión arterial de larga data Diabetes mellitus tipo 2 Fibrilación auricular permanente Motivo de consulta:…

[health-views-updates]

SGLT2 Inhibitors Market Growth and Market Trends 2024-2032

The SGLT2 Inhibitors Market Size was valued at USD 16.90 billion in 2024 and is projected to reach USD 29.73 billion by 2032, expanding at a robust CAGR of 7.33% during the forecast period of 2025–2032. With the global rise in type 2 diabetes and chronic kidney disease cases, SGLT2 inhibitors have emerged as a powerful therapy, gaining traction among both healthcare providers and patients.

Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated strong efficacy not only in glycemic control but also in reducing cardiovascular risks—an area that has piqued interest among clinicians worldwide. The drug class is becoming increasingly integral in treatment protocols, especially as guidelines evolve to reflect their cardiovascular and renal benefits.

Key Market Trends & Drivers:

Rising Incidence of Type 2 Diabetes: With the global diabetes population expected to exceed 700 million by 2045, the need for effective glycemic control medications like SGLT2 inhibitors is growing exponentially.

Expanded FDA Indications: Regulatory bodies have broadened the approved uses for SGLT2 inhibitors, including treatment for heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD).

Strategic Collaborations & Product Launches: Leading pharmaceutical companies are investing heavily in R&D, resulting in new drug formulations and strategic partnerships aimed at strengthening their market presence.

Patient Preference for Oral Therapy: Compared to injectable medications, the oral route of SGLT2 inhibitors offers convenience, improving adherence and treatment outcomes.

Regional Insights:

North America currently holds the lion’s share of the global market, thanks to well-established healthcare infrastructure, higher awareness levels, and favorable reimbursement policies. Meanwhile, Asia-Pacific is expected to witness the highest growth rate during the forecast period, propelled by rapid urbanization, dietary shifts, and increasing investment in healthcare systems.

Competitive Landscape:

The market is highly competitive with key players including AstraZeneca, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson (Janssen), and Merck. These companies are focused on innovation, post-marketing clinical trials, and expanding therapeutic indications to stay ahead in the evolving landscape.

Future Outlook:

Looking ahead, SGLT2 inhibitors are likely to become cornerstone therapies not just for diabetes, but also for managing multi-system chronic conditions like heart failure and kidney disease. Emerging research is also exploring their benefits in non-diabetic populations, opening the door to new patient segments and further growth.

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us: Akash Anand – Head of Business Development & Strategy 📧 info@snsinsider.com 📞 +1-415-230-0044 (US) | +91-7798602273 (IND)

[valencelabs]

Dapagliflozin Propanediol Monohydrate: Valence Labs

Dapagliflozin propanediol monohydrate is a widely used medication for managing type 2 diabetes mellitus. As a member of the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, it has shown remarkable efficacy in controlling blood sugar levels, improving cardiovascular health, and supporting kidney function.

What is Dapagliflozin Propanediol Monohydrate?

Dapagliflozin propanediol monohydrate is the monohydrate form of dapagliflozin, an active pharmaceutical ingredient. It works by blocking the SGLT2 protein in the kidneys, which reduces the reabsorption of glucose back into the bloodstream. As a result, excess glucose is expelled through the urine, effectively lowering blood sugar levels.

Uses of Dapagliflozin Propanediol Monohydrate

Management of Type 2 Diabetes: Primarily used to regulate blood glucose levels in adults with type 2 diabetes.

Heart Failure: Approved for treating heart failure with reduced ejection fraction (HFrEF).

Chronic Kidney Disease (CKD): Provides renal protection in patients with chronic kidney disease.

How Does Dapagliflozin Work?

Dapagliflozin inhibits the SGLT2 protein in the renal proximal tubules, preventing the kidneys from reabsorbing glucose into the bloodstream. By promoting urinary glucose excretion, it aids in blood sugar management. Additionally, it lowers blood pressure and reduces body weight, contributing to better cardiovascular outcomes.

Benefits of Dapagliflozin Propanediol Monohydrate

Improved Glycemic Control: Helps reduce HbA1c levels effectively.

Weight Management: Encourages weight loss due to calorie loss through glucose excretion.

Cardiovascular Protection: Reduces the risk of cardiovascular events such as heart attacks and strokes.

Kidney Protection: Slows the progression of chronic kidney disease.

[darkmaga-returns]

Ascertainment timeline. Time periods of ascertainment of baseline conditions, vital signs, medications, and exposure (AKI events) in relation to outcome (HF diagnosis date). Echocardiogram used to classify HF as HFpEF or HFrEF ascertained in 30 days before and up to 1 year following HF diagnosis date

One of the most glaring effects of the Spike Protein on the body (among many) is its apparent ability to induce Acute Kidney Injury (AKI). I believe this is something that clinicians need to be particularly aware of. After reviewing the evidence, it would seem prudent that any patients who have experienced AKI from COVID/Spike Transfection should be monitored for Heart Failure (HF). The connection between AKI and HF is the causative reason for concern.

First, let’s discuss how the Spike Protein may cause AKI. The most likely mechanism is the Spike Protein’s ability to mimic Acute Tubular Necrosis. It accomplishes this in a most devious manner.

The present study demonstrates that expression of the spike protein in HEK293-ACE2+ cells leads to cell fusion, progressive syncytia formation, and the lifting off and sloughing of sheets of fused cells from the monolayer, the latter giving rise to focal areas of denudation. These findings are reminiscent of what occurs during acute tubular injury/necrosis in AKI wherein injured renal epithelial cells, adhering to one another, detach from the tubular basement membrane and slough into the urinary space. The present study, to the best of our knowledge, is the first to call attention to this sloughing phenomenon in spike protein-expressing kidney cells and its mimicry of what may occur in the acute tubular necrosis variant of AKI. The relevance of syncytia to AKI is supported by a quite recent postmortem study in patients who died from COVID-19; in 28% of autopsy cases the presence of syncytia was reported in the kidney [23].

The spike protein of SARS-CoV-2 induces heme oxygenase-1: Pathophysiologic implications

[marksparksolutions]

Understanding Neprilysin Inhibitors in Heart Failure: A Game-Changer in Treatment

Heart failure (HF) is a prevalent condition affecting millions worldwide. Despite significant advancements in medical science, managing HF remains a challenge. However, neprilysin inhibitors have emerged as a revolutionary breakthrough in the treatment landscape, offering improved outcomes for patients.

Neprilysin is an enzyme responsible for breaking down beneficial peptides such as natriuretic peptides, which help regulate blood pressure, reduce fluid retention, and improve cardiac function. In heart failure patients, these peptides are essential for mitigating the disease's progression. Neprilysin inhibitors work by blocking the enzyme, thereby enhancing the beneficial effects of these peptides. This mechanism provides dual benefits: improved heart function and reduced strain on the cardiovascular system.

One notable example of this innovative approach is the combination of neprilysin inhibitors with angiotensin receptor blockers (ARBs), such as sacubitril/valsartan. Clinical trials have demonstrated the efficacy of this combination in reducing hospitalizations and mortality rates among heart failure patients with reduced ejection fraction (HFrEF). These therapies represent a paradigm shift, offering hope to those who previously faced limited treatment options.

At Mark Spark Solutions, we aim to shed light on transformative medical advancements like neprilysin inhibitors, emphasizing their critical role in reshaping patient care. By addressing the underlying causes of heart failure and targeting pathways that improve cardiac efficiency, these inhibitors mark a significant step forward in cardiovascular medicine.

However, like any medical treatment, neprilysin inhibitors require careful evaluation by healthcare providers. They may not be suitable for everyone, particularly patients with certain conditions such as severe renal impairment or a history of angioedema. Collaboration between patients and their healthcare teams is essential to ensure the best outcomes.

As the heart failure market evolves, the role of neprilysin inhibitors will continue to expand, influencing treatment protocols and improving the quality of life for millions. To learn more about advancements in heart failure treatment and other innovative healthcare solutions, visit Mark Spark Solutions today.

By staying informed about the latest developments, we can pave the way for a healthier, more hopeful future.

[myrawjcsmicasereports]

 Resolution of QRS-fragmentation: A case report and review of literature by Zhong Yi, MD in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

Background: It’s not clear whether the resolution of fQRS can be used to assess the effectiveness of cardiac resynchronization therapy defibrillator (CRT-D) in patients of heart failure with reduced ejection fraction (HFrEF).

Case presentation: Here we report a 78-year-old male patient with HFrEF and refractory ventricular tachycardia (VT), who’s 12-lead electrocardiogram (ECG) showed fQRS in leads V1-V6 with QRS duration of 134 ms on admission. Even though the optimized medication of metoprolol, amiodarone, lidocaine, and berberine was given, the recurrent VT and HFrEF were still refractory. For further management, a CRT-D with multipoint pacing (MPP) function (St. Jude Medical, Sylmar, CA) was considered and implanted. It’s very encouraging that no more VTs and fQRS were recorded 9 hours after a CRT-D with MPP function was implanted, and the left ventricle ejection fraction (LVEF) improved significantly later.

Conclusion: CRT-D with MPP is effective in improving the situation of the patient with ischemic cardiomyopathy and HFrEF, and the fQRS resolution can be considered as a sign of its effectiveness.

Keywords: Fragmented QRS; Heart failure; Cardiac resynchronization therapy; Multipoint pacing

Introduction

Fragmented QRS (fQRS) on the 12-lead electrocardiogram (ECG) is defined as the presence of additional notches buried within the QRS, which is widely accepted as a sign of myocardial infarction scar or fibrosis. [1, 2] The fQRS is derived from the abnormality of ventricular depolarization due to ventricular heterogeneity and derangement of ventricular conduction around the infarction zone or scar. [3-5]  And the fQRS is also a sign of left ventricular desynchronization in patients of heart failure with reduced ejection fraction (HFrEF) and the narrow QRS complex (<150 ms). [6] A meta-analysis showed that fQRS on patient’s baseline ECG increased all-cause mortality and major arrhythmic events in HFrEF patients. [7] However, it’s not clear whether the resolution of fQRS is useful to assess the effectiveness of cardiac resynchronization therapy defibrillator (CRT-D) in patients with ischemic cardiomyopathy, especially those CRT-D with multipoint pacing (MPP) function. Here we present an HFrEF patient who had fQRS on his admission ECG and frequent ventricular tachycardia (VT) on his Ambulatory ECG. But no more VT and fQRS were recorded, 9 hours after the implantation of a CRT-D with MPP function. The patient had provided informed consent for publication of this case.

Case presentation

A 78-year-old man presented with a complaint of chest congestion and short of breath lasted for 2 hours on his admission. He had hypertension for 10 years, but his blood pressure was normal on admission without taking any medicine. He had an old myocardial infarction and a coronary artery stent implanted 18 years before, and 2 more stents implanted 10 years before. The patient took a semi-sitting position, the blood pressure was 105/65 mmHg, and the heart rate was 80 bpm. Both lungs were clear, the apex was left out of the normal limit, and slight edema in lower extremities was found. His laboratory examination, including blood routine, hepatic and renal function, electrolyte, coagulation function, and Cardiac troponin I (CTNI), was normal, but the level of brain natriuretic peptide (BNP) elevated to 3082 pg/ml. The ECG showed sinus rhythm, ventricular bigeminy, fQRS in leads V1-V6, QRS duration of 134 ms, and abnormal Q wave in leads V4-V6 (Fig. 1a). His 24-hours Holter monitoring showed 41,320 polymorphic ventricular premature beats (PVCs), which is 42% of the total 98327 beats, and 254 paroxysmal polymorphic VT (Fig. 2a). His chest x-radiography revealed pulmonary congestion, pear-shaped heart and cardio-thoracic proportion of more than 50% (Fig. 3a). His transthoracic echocardiography showed left atrium and ventricle enlargement with the left ventricular end-diastolic diameter of 62 mm; there was a ventricular aneurysm of 5.2×2.0 cm2; there was minor regurgitation of mitral and aortic valves; the left ventricular ejection fraction (LVEF) was 28%. Moreover, no coronary artery or stent stenosis was shown by coronary angiography. We proposed the patient’s primary diagnosis was ischemic cardiomyopathy and HFrEF. Even though the optimized medication of metoprolol, amiodarone, lidocaine, and berberine was given, the recurrent VT and HFrEF were still refractory. For further management, a CRT-D with MPP function (St. Jude Medical, Sylmar, CA) was considered and implanted. It’s very encouraging that 9 hours after the procedure, no VT was monitored again (Fig. 2b); twenty-four hours later, the fQRS was absent and never been recorded after that, and the QRS duration decreased from 134 ms to 122 ms (Fig. 1b). Also, the level of BNP significantly dropped to 357 pg/ml. Furthermore, nine days after the procedure, the LVEF increased to 45%; 30 days later, no pulmonary congestion was found on his Chest x-radiography and the cardio-thoracic proportion improved significantly (Fig. 3b). While, over one year of follow-up, the patient has remained symptom-free of VT and HF.

The patient’s chest x-radiography revealed pulmonary congestion, pear-shaped heart, and cardio-thoracic proportion more than 50% at baseline; (b) There was no pulmonary congestion, and the cardio-thoracic percentage decreased significantly, 30 days after the CRT-D implantation.

Discussion

Considering this patient’s old MI history, we supposed that the possible reason for short of breath on admission was acute myocardial ischemia or acute heart failure. But there was no coronary artery or stent stenosis on his coronary angiography, and the level of CTNI was normal. Combined with clinical signs, chest x-radiography, echocardiographic signs, and elevated levels of BNP, the reason for short of breath was sure to be acute heart failure.

The fQRS is defined as various ‘RSR’ patterns, with or without a Q wave, located in two contiguous leads of a major coronary artery territory. And, the fQRS manifests as an extra R (R’) wave, ≥2 notches in R wave, or ≥2 notches in the down or up-stroke of S wave.[4] It’s reported that fQRS was associated with myocardial infarction scar or fibrosis, and was considered as a sign of old myocardial infarction. [1, 2] The fQRS was also considered as a marker of left ventricular dyssynchrony in HFrEF patients with narrow QRS complex (<150ms). [6] Furthermore, the fQRS was also associated with higher all-cause mortality, and cardiac event rate defined as MI, need for revascularization, VT and cardiac death. [8, 9] The fQRS found in contiguous 3 leads was a significant predictor of the cardiac death or heart failure hospitalization. [9] fQRS increased MAE in HFrEF patients. [7] In this HFrEF patient, the fQRS, with narrow QRS complex of 134 ms, presented on all the 6 precordial leads (V1-V6) on his admission ECG. As it was discussed on the above, the presence of fQRS, with narrow QRS complex on the ECG, was showed that he had left ventricular dyssynchrony caused by myocardial infarction scar or fibrosis. Therefore, our strategy focused on improving the ischemic cardiomyopathy induced HFrEF, and CRT-D with MPP was the best choice for the management of his refractory VT and HFrEF. Practically, the complete resolution of fQRS accompanied by the improvement of HFrEF in a relatively short hospital stay is strong evidence support for the effectiveness of CRT-D with MPP function.

Implantable CRT with MPP is a new quadripolar technology that involves a left ventricle lead with 4 different pacing electrodes and a dedicated device with multiple pacing options. [9] MPP is superior to the conventional biventricular pacing on the improvement of acute cardiac hemodynamics, left ventricle synchronization, and QRS complex narrowing, and all of this manifested as a higher number of acute responders to CRT. [10-12] Therefore, a CRT-D with MPP was implanted in our patient. Then, he had a significant improvement, such as the termination of VT, the narrowing of QRS, the elevation of LVEF, and the relief of HF symptoms.

In conclusion, CRT-D with MPP is very useful in improving the LVEF of the patient with ischemic cardiomyopathy and HFrEF. And the resolution of fQRS may be a sign of the alleviation of HFrEF by using CRT-D with MPP.

[hardoctornews]

Scompenso cardiaco: ferro endovenoso efficace indipendentemente dall’età

L’integrazione di ferro endovenoso con derisomaltosio ferrico (FDI) ha dimostrato benefici nei pazienti con scompenso cardiaco a frazione di eiezione ridotta (HFrEF) e carenza marziale, ma il suo effetto in diverse fasce d’età rimaneva poco chiaro. Un’analisi dello studio IRONMAN, pubblicata su Heart, ha valutato l’efficacia e la sicurezza del trattamento con FDI stratificando i pazienti in base…

[market-insider]

Southeast Asia Pacemakers Market Insights: Detailed Overview of Market Size, Share, Projected Growth

The Southeast Asia pacemakers market size is expected to reach USD 97.67 million by 2030 and is projected to grow at a CAGR of 5.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. South East Asia is witnessing a significant demographic shift towards an older population. Older individuals are more susceptible to heart-related issues, which increases the need for pacemakers. This aging trend is accelerating the demand for devices that help manage heart rhythm disorders. Moreover, the increasing prevalence of cardiovascular diseases, such as arrhythmias and heart block, is a major driver for the market.

South East Asia Pacemakers Market Report Highlights

The external pacemakers segment held the largest share of more than 50.0% in 2023 due to their widespread use is due to their versatility, ease of application, and the immediate, adjustable support they offer.

The conventional pacemakers segment held the largest share of around 60.0% in 2023. These devices have a long track record of effectiveness in treating bradycardia (slow heart rate) and other arrhythmias.

In 2023, the congestive heart failure (CHF) segment dominated the market, capturing a significant 33.18% share.

Hospitals & cardiac centers held the largest share of 42.27% in 2023. The availability of advanced diagnostic tools, surgical facilities, and post-operative care makes hospitals the preferred setting for pacemaker procedures.

For More Details or Sample Copy please visit link @: South East Asia Pacemakers Market Report

A report from the National Library of Medicine published in April 2024 highlights significant variations in heart failure classifications across Southeast Asia. The INTER-CHF study reveals that 39% of heart failure patients in Malaysia and the Philippines have a reduced left ventricular ejection fraction (LVEF) of less than 40%. Conversely, data from the International REPORT-HF registry shows that in Indonesia, and Thailand, the distribution of heart failure types is 59% HFrEF (heart failure with reduced ejection fraction), 18% HFmrEF (heart failure with mid-range ejection fraction), and 23% HFpEF (heart failure with preserved ejection fraction). Additionally, the NHFR (National Heart Failure Registry of India) reports that HFrEF is the most common classification in South Asia, affecting 65% of patients, followed by HFmrEF at 22% and HFpEF at 13%.

Moreover, government initiatives across Southeast Asia play a crucial role in enhancing access to cardiac pacemakers and improving overall cardiovascular care. The governments are upgrading healthcare infrastructure and modernizing hospitals to include advanced cardiac units, improving access to pacemaker treatments. Initiatives like the Philippines' Universal Health Care (UHC) Law enhance coverage and reduce financial barriers, making advanced cardiac care more accessible to a wider population.

List of major companies in the Southeast Asia Pacemakers Market

Boston Scientific Corporation

Medtronic

BIOTRONIK SE & Co. KG

MicroPort Scientific Corporation

Abbott

Lepu Medical Technology(Beijing)Co.,Ltd.

For Customized reports or Special Pricing please visit @: South East Asia Pacemakers Market Report

We have segmented the Southeast Asia pacemakers market based on product, type, application, end-use and country.

[shobhaalss]

Empagliflozin

Empagliflozin is an oral medication used primarily in the treatment of type 2 diabetes. Here's a concise overview of key points about empagliflozin:

1. Drug class: It belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors.

2. Mechanism of action: Empagliflozin works by helping the kidneys remove excess sugar from the body through urine.

3. Brand names: The most common brand name is Jardiance, manufactured by Boehringer Ingelheim and Eli Lilly.

4. Uses:

   - Primary use: Treatment of type 2 diabetes

   - Secondary uses: Reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

   - Treatment of heart failure with reduced ejection fraction (HFrEF)

5. Administration: Taken orally, usually once daily.

6. Common side effects: Urinary tract infections, genital mycotic infections, and increased urination.

7. Benefits: Besides glucose control, it has shown cardiovascular and renal protective effects.

8. Contraindications: Not recommended for patients with type 1 diabetes or diabetic ketoacidosis.

Would you like more detailed information on any specific aspect of empagliflozin, such as its efficacy, dosing, or potential drug interactions?

[drdavidburkett]

Innovative Strategies in Heart Failure Management: Elevating Patient Care and Outcomes

Heart failure is a pervasive and life-altering condition that affects millions of individuals globally. Characterized by the heart's inability to pump blood effectively, heart failure can lead to significant morbidity, frequent hospitalizations, and an overall diminished quality of life. The complexity of managing heart failure necessitates a dynamic and comprehensive approach that integrates the latest advancements in medical treatments, lifestyle interventions, patient education, and multidisciplinary care. This article delves into contemporary strategies for managing heart failure, emphasizing the collective commitment required to enhance patient outcomes and transform lives.

The Complex Nature of Heart Failure

Heart failure occurs when the heart is unable to pump blood efficiently, leading to a buildup of fluid in the lungs and other tissues. This condition can result from a variety of causes, including coronary artery disease, high blood pressure, diabetes, and chronic alcohol use. Heart failure is typically categorized into two types: heart failure with reduced ejection fraction (HFrEF), where the heart muscle is weakened and unable to contract properly, and heart failure with preserved ejection fraction (HFpEF), where the heart muscle is stiff and cannot relax adequately.

The symptoms of heart failure, which can include shortness of breath, fatigue, swelling in the legs, and difficulty performing daily activities, often worsen over time. The progressive nature of the disease can lead to recurrent hospitalizations, decreased independence, and a significant impact on patients' mental and emotional well-being.

Advancements in Pharmacological Treatments

The treatment landscape for heart failure has evolved remarkably over the past few decades, with new pharmacological therapies offering significant improvements in patient outcomes. These medications are designed not only to alleviate symptoms but also to target the underlying mechanisms of the disease, thereby slowing its progression and reducing the risk of hospitalization and death.

Angiotensin Receptor-Neprilysin Inhibitors (ARNIs): ARNIs have emerged as a groundbreaking therapy for patients with HFrEF. By simultaneously blocking the effects of angiotensin II and inhibiting the enzyme neprilysin, these drugs help reduce blood pressure, decrease heart strain, and improve overall heart function.

SGLT2 Inhibitors: Initially developed as a treatment for type 2 diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated profound benefits in heart failure management. These medications not only help manage blood sugar levels but also reduce the risk of heart failure hospitalization and cardiovascular death, making them a valuable addition to the treatment arsenal.

Mineralocorticoid Receptor Antagonists (MRAs): MRAs, such as spironolactone and eplerenone, have been shown to significantly improve outcomes in patients with heart failure by reducing fluid retention, decreasing blood pressure, and minimizing the risk of sudden cardiac death.

Ivabradine: For patients with HFrEF who are in sinus rhythm and have a resting heart rate above 70 beats per minute, ivabradine offers an effective means of reducing heart rate and improving heart function, thereby lowering the likelihood of hospitalization.

Device-Based Interventions

In addition to pharmacological treatments, device-based therapies have become a cornerstone of heart failure management, particularly for patients with advanced disease or those at high risk of arrhythmias.

Implantable Cardioverter-Defibrillators (ICDs): ICDs are small devices implanted in the chest that monitor heart rhythms and deliver electric shocks when life-threatening arrhythmias are detected. For patients with heart failure, ICDs can prevent sudden cardiac death and significantly improve survival rates.

Cardiac Resynchronization Therapy (CRT): CRT devices help coordinate the contractions of the heart's chambers, improving the efficiency of the heart's pumping action. This therapy is particularly beneficial for patients with heart failure and a specific type of abnormal heart rhythm known as left bundle branch block (LBBB).

Left Ventricular Assist Devices (LVADs): For patients with severe heart failure who are not candidates for heart transplantation, LVADs offer a life-sustaining option. These mechanical pumps assist the heart in circulating blood throughout the body, significantly extending life expectancy and improving quality of life.

The Crucial Role of Lifestyle Modifications

While medical treatments are essential, lifestyle modifications are equally important in managing heart failure and improving long-term outcomes. Patients are encouraged to adopt heart-healthy habits that can mitigate symptoms, enhance overall health, and reduce the risk of disease progression.

Dietary Adjustments: A heart-healthy diet is a fundamental aspect of heart failure management. Patients are advised to limit sodium intake to reduce fluid retention and avoid foods high in saturated fats, trans fats, and cholesterol to support cardiovascular health. Incorporating a variety of fruits, vegetables, whole grains, and lean proteins can provide essential nutrients and promote heart function.

Regular Physical Activity: Engaging in regular physical activity, tailored to the individual's capabilities and condition, can improve cardiovascular fitness, increase energy levels, and enhance quality of life. Cardiac rehabilitation programs, which offer structured exercise regimens and education, are particularly beneficial for heart failure patients.

Weight Management: Maintaining a healthy weight is crucial for individuals with heart failure, as obesity can exacerbate symptoms and increase the risk of comorbidities. Weight loss strategies, including dietary changes and increased physical activity, are recommended for overweight patients to improve heart function and reduce the burden on the cardiovascular system.

Smoking Cessation: Smoking is a significant risk factor for heart disease and can worsen heart failure. Quitting smoking is one of the most impactful lifestyle changes a patient can make, leading to improved heart function and a reduced risk of complications. Healthcare providers should offer support through counseling, nicotine replacement therapy, and other cessation programs.

Patient-Centered Care and Education

Empowering patients through education and active involvement in their care is essential for optimizing heart failure management. Patients who understand their condition and treatment options are better equipped to make informed decisions and adhere to prescribed therapies.

Comprehensive Education: Providing patients with clear, concise information about heart failure, its symptoms, and the importance of treatment adherence is critical. Education should also cover self-management techniques, such as monitoring weight and recognizing early signs of decompensation, to enable patients to take proactive steps in managing their condition.

Medication Adherence: Adherence to prescribed medications is a key determinant of successful heart failure management. Healthcare providers should work closely with patients to address potential barriers to adherence, such as complex dosing regimens, side effects, and medication costs. Simplifying treatment plans and using reminder tools can help improve adherence rates.

Support Systems: Building a robust support system is vital for heart failure patients. Family members, caregivers, and healthcare professionals can provide emotional support, practical assistance, and encouragement, helping patients navigate the challenges of living with heart failure. Support groups, both in-person and online, can also offer valuable resources and a sense of community.

The Multidisciplinary Approach to Heart Failure Management

The complexity of heart failure necessitates a multidisciplinary approach to care, with collaboration among various healthcare professionals to address the diverse needs of patients. This approach ensures that patients receive comprehensive care that addresses not only their physical symptoms but also their emotional, social, and psychological well-being.

Integrated Care Teams: A successful heart failure management strategy involves the collaboration of cardiologists, primary care physicians, nurses, dietitians, pharmacists, and social workers. These professionals work together to develop personalized care plans, coordinate treatments, and monitor patient progress, ensuring that all aspects of the patient's health are addressed.

Palliative Care Integration: For patients with advanced heart failure, integrating palliative care into the treatment plan can significantly improve quality of life. Palliative care focuses on symptom management, pain relief, and emotional support, helping patients and their families navigate the challenges of advanced disease.

Telehealth and Remote Monitoring: The use of telehealth and remote monitoring technologies has expanded significantly in recent years, offering new opportunities for managing heart failure. These tools allow healthcare providers to monitor patients' vital signs and symptoms in real-time, enabling early intervention and reducing the need for hospital visits. Telehealth also enhances access to care for patients in remote or underserved areas.

The Future of Heart Failure Management

As we look to the future, ongoing research and technological advancements promise to further revolutionize heart failure management and improve patient outcomes.

Personalized Medicine: Advances in genetic research and biomarker identification are paving the way for personalized medicine in heart failure treatment. By tailoring therapies to an individual's genetic makeup and specific disease characteristics, personalized medicine has the potential to optimize treatment efficacy and minimize side effects.

Regenerative Medicine: Research into stem cell therapy and other regenerative treatments offers hope for the future of heart failure management. These therapies aim to repair damaged heart tissue and restore normal heart function, potentially reversing the effects of heart failure.

Artificial Intelligence (AI) and Big Data: The integration of AI and big data analytics into heart failure management is poised to transform the field. AI algorithms can analyze vast amounts of patient data to identify patterns, predict outcomes, and guide treatment decisions, leading to more precise and effective care.

Heart failure management has made significant strides in recent years, with advances in pharmacological treatments, device-based therapies, lifestyle modifications, and patient-centered care all contributing to improved outcomes. However, the journey is far from over. A continued commitment to innovation, education, and multidisciplinary collaboration is essential to further enhance patient care and quality of life. By embracing new technologies, personalized approaches, and a holistic view of patient well-being, we can continue to make meaningful progress in the fight against heart failure and offer hope to millions of individuals around the world.

[rnomics]

IJMS, Vol. 25, Pages 6661: Hypertension and Heart Failure: From Pathophysiology to Treatment

Hypertension represents one of the primary and most common risk factors leading to the development of heart failure (HF) across the entire spectrum of left ventricular ejection fraction. A large body of evidence has demonstrated that adequate blood pressure (BP) control can reduce cardiovascular events, including the development of HF. Although the pathophysiological and epidemiological role of hypertension in the development of HF is well and largely known, some critical issues still deserve to be clarified, including BP targets, particularly in HF patients. Indeed, the management of hypertension in HF relies on the extrapolation of findings from high-risk hypertensive patients in the general population and not from specifically designed studies in HF populations. In patients with hypertension and HF with reduced ejection fraction (HFrEF), it is recommended to combine drugs with documented outcome benefits and BP-lowering effects. In patients with HF with preserved EF (HFpEF), a therapeutic strategy with all major antihypertensive drug classes is recommended. Besides commonly used antihypertensive drugs, different evidence suggests that other drugs recommended in HF for the beneficial effect on cardiovascular outcomes exert advantageous blood pressure-lowering actions. In this regard, type 2 sodium glucose transporter inhibitors (SGLT2i) have been shown to induce BP-lowering actions that favorably affect cardiac afterload, ventricular arterial coupling, cardiac efficiency, and cardiac reverse remodeling. More recently, it has been demonstrated that finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Other proposed agents, such as endothelin receptor antagonists, have provided contrasting results in the management of hypertension and HF. A novel, promising strategy could be represented by small interfering #RNA, whose actions are under investigation in ongoing clinical trials. https://www.mdpi.com/1422-0067/25/12/6661?utm_source=dlvr.it&utm_medium=tumblr